NAC for PCOS and Endometriosis: Glutathione Pathway, RCT Data, and Fertility Evidence

[Image: Pathway diagram: NAC → cysteine → glutathione synthesis; GSH neutralizing H2O2 via GPx; NAC blocking NF-κB → IL-6/TNF-α reduction]

Glutathione (GSH) is a tripeptide (glycine-cysteine-glutamate) synthesized intracellularly. The rate-limiting step is cysteine availability — NAC provides the acetylated cysteine that is rapidly deacetylated intracellularly to free cysteine. NAC therefore directly augments GSH synthesis without the bioavailability limitations of exogenous GSH supplementation (which undergoes hydrolysis in the gut).

GSH functions as the cell's primary reducing agent via glutathione peroxidase, neutralizing hydrogen peroxide, lipid hydroperoxides, and reactive nitrogen species. In the context of PCOS, elevated reactive oxygen species (ROS) in both ovarian tissue and follicular fluid impair: (1) oocyte meiotic spindle assembly, (2) mitochondrial membrane potential in oocytes, and (3) insulin receptor tyrosine kinase phosphorylation — the latter directly linking oxidative stress to insulin resistance.

NAC also inhibits NF-κB nuclear translocation, reducing transcription of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) that are elevated in both PCOS ovarian tissue and endometriotic lesions.

A double-blind RCT by Rizk et al. (2005, n=100) compared NAC 1800mg/day to metformin 1500mg/day in clomiphene-resistant PCOS. NAC achieved equivalent ovulation induction rates (52% vs 47%, NS difference) and comparable reductions in fasting insulin and testosterone. A 2015 Cochrane-adjacent systematic review of 5 RCTs (n=426) found NAC superior to placebo for ovulation rate (OR 2.82, 95% CI 1.54-5.18) and pregnancy rate, with similar effect sizes to metformin.

Mechanistically, the insulin-sensitizing effect of NAC is independent of the AMPK pathway used by berberine/metformin. Instead, NAC reduces ROS-mediated serine phosphorylation of IRS-1 (insulin receptor substrate-1) — a modification that inhibits PI3K/AKT signaling. By restoring IRS-1 tyrosine phosphorylation (the productive signaling event), NAC enhances downstream insulin signaling without directly activating AMPK. This distinct mechanism supports combination use with other insulin sensitizers.

[Image: Comparison bar chart: endometrioma cyst size reduction rates in NAC vs control group from Marziali 2012 study]

Endometriosis involves ectopic endometrial implants sustained by elevated local ROS, angiogenesis, and immune evasion — all of which NAC theoretically addresses. Marziali et al. (2012) conducted a randomized trial comparing NAC 600mg TID (3 days on, 4 days off cycling) to no treatment in endometrioma patients. After 3 months:

• 22/47 NAC patients showed cyst size reduction vs. 8/44 controls (OR 3.3, p=0.009) • 9 NAC patients had cysts disappear entirely vs. 4 controls • More NAC patients cancelled scheduled cystectomy due to improvement (21% vs 8%)

The cycling protocol (3 days on, 4 days off) was designed to avoid potential mucus-thinning effects on endometrial receptivity during implantation windows. The study is limited by its open-label design and relatively small n, but represents the strongest specific endometriosis evidence for any non-pharmaceutical supplement.

Oocyte quality is critically dependent on mitochondrial function — oocytes contain ~100,000 mitochondria (the highest density of any human cell) because fertilization, meiotic resumption, and early embryogenesis are entirely dependent on oocyte-derived ATP. Mitochondrial ROS accumulation with maternal age and pathological states (PCOS, endometriosis) impairs meiotic spindle integrity and increases aneuploidy risk.

Follicular fluid GSH concentrations correlate positively with oocyte maturity rates and embryo quality in IVF cycles. NAC supplementation (600mg TID) for 3 months pre-IVF has demonstrated improved follicular fluid antioxidant capacity in small studies. A prospective cohort (Cheraghi et al., 2016) found NAC pre-treatment improved oocyte maturation and fertilization rates in poor responders (AFC <5).

For women 35-42 undergoing IVF — the age range where oocyte mitochondrial function is most compromised — the theoretical benefit of pre-cycle NAC is greatest, though adequately powered RCTs specifically in this population are lacking.

Pharmacokinetics: NAC is rapidly absorbed orally (peak plasma at 1-2h) with ~10% bioavailability due to hepatic first-pass deacetylation and GSH incorporation. The relatively low plasma bioavailability is offset by direct tissue uptake and intracellular conversion; GSH synthesis occurs at the target cell level.

Evidence-based dosing: • PCOS/insulin sensitization: 600mg TID (1,800mg/day) • Endometriosis: 600mg TID with cycling protocol (3 days on, 4 days off) per Marziali • Pre-IVF egg quality: 600mg TID for 8-12 weeks pre-retrieval

Safety: NAC is well-established with decades of clinical use in acetaminophen toxicity (IV) and COPD (oral). Oral GI adverse effects (nausea, diarrhea) are dose-dependent and reduced by food co-administration. High-dose NAC (>3g/day) has been associated with reduced platelet aggregation; clinically relevant at PCOS/endometriosis doses is uncommon. No teratogenicity demonstrated; used in pregnancy in specific clinical contexts (acetaminophen overdose), but routine peri-conception use should be discussed with a reproductive endocrinologist.